Drug Type Small molecule drug |
Synonyms ERK-IN-1, LTT-462 |
Target |
Mechanism ERK1 inhibitors(Extracellular-signal-regulated kinase1 inhibitors), ERK2 inhibitors(Extracellular-signal-regulated kinase 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseIND Approval |
First Approval Date- |
Regulation- |
Molecular FormulaC26H27BrF3N5O2 |
InChIKeyYFCIFWOJYYFDQP-PTWZRHHISA-N |
CAS Registry1715025-32-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Melanoma | Phase 2 | US | 30 Oct 2020 | |
Melanoma | Phase 2 | AU | 30 Oct 2020 | |
Melanoma | Phase 2 | AT | 30 Oct 2020 | |
Melanoma | Phase 2 | BE | 30 Oct 2020 | |
Melanoma | Phase 2 | FR | 30 Oct 2020 | |
Melanoma | Phase 2 | DE | 30 Oct 2020 | |
Melanoma | Phase 2 | IL | 30 Oct 2020 | |
Melanoma | Phase 2 | NL | 30 Oct 2020 | |
Melanoma | Phase 2 | NO | 30 Oct 2020 | |
Melanoma | Phase 2 | CH | 30 Oct 2020 |